Partial
Partially Aligned
Patient Risk:
Moderate
Summary
The mortality-in-elderly-dementia-related-psychosis portion is supported by the label (5.1). The suicidal thoughts/behaviors portion is not adequately supported as a SEROQUEL-specific association; the provided label excerpt (5.2) discusses suicidal thoughts/behaviors with antidepressants in MDD rather than attributing this risk to SEROQUEL.
Category Scores
Accurate Statements
SEROQUEL increases mortality in elderly patients with dementia-related psychosis.
Warnings and Precautions (5.1): elderly patients with dementia-related psychosis treated with antipsychotic drugs have increased risk of death; includes drug-treated vs placebo rates; SEROQUEL is not approved for dementia-related psychosis.
SEROQUEL is not approved for the treatment of patients with dementia-related psychosis.
Warnings and Precautions (5.1): "SEROQUEL is not approved for the treatment of patients with dementia-related psychosis."
Unsupported Statements
SEROQUEL is associated with suicidal thoughts/behaviors.
The provided label excerpt (5.2) addresses suicidal thoughts and behaviors risk in adolescents and young adults receiving antidepressants for MDD and monitoring requirements for antidepressant-treated patients; it does not explicitly attribute suicidal thoughts/behaviors to SEROQUEL.
Contradictions
Important Omissions
A clarifying statement that the suicidal thoughts/behaviors language in the cited label section (5.2) pertains to antidepressants used for MDD (and does not explicitly state that SEROQUEL itself causes/causally increases suicidal thoughts/behaviors).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Mortality claim for dementia-related psychosis is on-label. The suicidal thoughts/behaviors claim is overgeneralized beyond the provided SEROQUEL label excerpt, which could lead to misunderstanding of the label scope.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Partially Aligned
Primary Issue
Suicidal thoughts/behaviors described as an association with SEROQUEL is not directly supported by the provided label excerpt (5.2), which focuses on antidepressants for MDD.
Suggested Improvement
Limit the suicidal thoughts/behaviors statement to what the label excerpt supports (antidepressant-related risk in adolescents/young adults with MDD and monitoring instructions), or explicitly state the label does not attribute this risk specifically to SEROQUEL in the provided text.